Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
KalVista Pharmaceuticals ( (KALV) ) has shared an announcement.
On January 8, 2026, KalVista Pharmaceuticals reported preliminary unaudited global net product revenue for EKTERLY (sebetralstat) of approximately $35 million for the fourth quarter and $49 million for full-year 2025, following the US commercial launch on July 7, 2025. The company highlighted rapid uptake of EKTERLY, with 1,318 patient start forms and 580 unique US prescribers recorded by December 31, 2025, and noted that prescription refills overtook initial prescriptions as the main revenue driver in the fourth quarter, indicating growing real-world use and patient retention. KalVista also emphasized strong early adoption in Germany and expanded its commercial footprint through a new partnership with Multicare Pharmaceuticals to commercialize sebetralstat in key Latin American markets, complementing earlier licensing deals in Japan and Canada. During 2025 the company secured regulatory approvals for EKTERLY in seven major global markets and completed enrollment in the Phase 3 KONFIDENT-KID trial in pediatric HAE patients aged 2–11 years a year ahead of schedule, positioning EKTERLY as a potential foundational treatment in HAE and underscoring KalVista’s strengthening commercial and regulatory position in the rare-disease therapeutics space.
The most recent analyst rating on (KALV) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on KalVista Pharmaceuticals stock, see the KALV Stock Forecast page.
Spark’s Take on KALV Stock
According to Spark, TipRanks’ AI Analyst, KALV is a Neutral.
The score is held down primarily by very large losses, heavy cash burn, and a sharply reduced equity cushion despite improving revenue. Technicals are mixed but not severely negative, valuation lacks support due to negative earnings and no dividend, and recent leadership changes provide a modest positive offset.
To see Spark’s full report on KALV stock, click here.
More about KalVista Pharmaceuticals
KalVista Pharmaceuticals is a global pharmaceutical company focused on developing and commercializing therapies for rare diseases with significant unmet medical needs. The company discovered and developed EKTERLY (sebetralstat), the first and only oral on-demand treatment for acute attacks of hereditary angioedema (HAE), and works closely with the global HAE community, targeting patients initially aged 12 and older across multiple major markets including the US, EU, UK, Switzerland, Australia, Singapore and Japan.
Average Trading Volume: 1,246,366
Technical Sentiment Signal: Buy
Current Market Cap: $796.1M
Find detailed analytics on KALV stock on TipRanks’ Stock Analysis page.